Literature DB >> 28283656

The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker.

Brit Mollenhauer1,2,3, Daniel Weintraub4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28283656      PMCID： PMC5373331          DOI： 10.1073/pnas.1700737114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  10 in total

Review 1.  Neuropathology underlying clinical variability in patients with synucleinopathies.

Authors:  Glenda M Halliday; Janice L Holton; Tamas Revesz; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2011-07-01       Impact factor: 17.088

Review 2.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

3.  Monitoring of 30 marker candidates in early Parkinson disease as progression markers.

Authors:  Brit Mollenhauer; Johannes Zimmermann; Friederike Sixel-Döring; Niels K Focke; Tamara Wicke; Jens Ebentheuer; Martina Schaumburg; Elisabeth Lang; Ellen Trautmann; Henrik Zetterberg; Peggy Taylor; Tim Friede; Claudia Trenkwalder
Journal:  Neurology       Date:  2016-05-06       Impact factor: 9.910

4.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

5.  Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease.

Authors:  Holly Green; Xiaoqun Zhang; Katarina Tiklova; Nikolaos Volakakis; Lovisa Brodin; Louise Berg; Paul Greengard; Thomas Perlmann; Per Svenningsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 6.  p11 and its role in depression and therapeutic responses to antidepressants.

Authors:  Per Svenningsson; Yong Kim; Jennifer Warner-Schmidt; Yong-Seok Oh; Paul Greengard
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

Review 7.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.

Authors:  Brit Mollenhauer; Omar M A El-Agnaf; Katrin Marcus; Claudia Trenkwalder; Michael G Schlossmacher
Journal:  Biomark Med       Date:  2010-10       Impact factor: 2.851

8.  Annexin A2, autoimmunity, anxiety and depression.

Authors:  R Weiss; A Bitton; M Ben Shimon; S Elhaik Goldman; L Nahary; I Cooper; I Benhar; C G Pick; J Chapman
Journal:  J Autoimmun       Date:  2016-06-29       Impact factor: 7.094

9.  Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.

Authors:  Charles H Adler; Thomas G Beach; Joseph G Hentz; Holly A Shill; John N Caviness; Erika Driver-Dunckley; Marwan N Sabbagh; Lucia I Sue; Sandra A Jacobson; Christine M Belden; Brittany N Dugger
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

10.  Prediagnostic presentations of Parkinson's disease in primary care: a case-control study.

Authors:  Anette Schrag; Laura Horsfall; Kate Walters; Alastair Noyce; Irene Petersen
Journal:  Lancet Neurol       Date:  2014-11-27       Impact factor: 44.182
  10 in total
  1 in total

1.  Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson's disease and schizophrenia.

Authors:  Ashish Kumar Gupta; Ruchika Pokhriyal; Uddipan Das; Mohd Imran Khan; Domada Ratna Kumar; Rishab Gupta; Rakesh Kumar Chadda; Rashmi Ramachandran; Vinay Goyal; Manjari Tripathi; Gururao Hariprasad
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-19       Impact factor: 2.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.